In this video, Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, briefly discusses the safety and efficacy of isatuximab, bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed transplant-eligible multiple myeloma as observed in the GMMG HD7 trial (NCT03617731). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.